41014-44-2

Usage

Uses

Used in Pharmaceutical Industry:
2-(CHLOROMETHYL)-5-METHYL-1,3-BENZOXAZOLE is used as an intermediate in the manufacturing of pharmaceuticals for its potential role in the development of new drugs. Its unique structure allows it to be a key component in the synthesis of various medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical industry, 2-(CHLOROMETHYL)-5-METHYL-1,3-BENZOXAZOLE is utilized as a building block in the creation of agrochemicals, contributing to the development of effective pesticides and other agricultural products.
Used in Materials Science:
2-(CHLOROMETHYL)-5-METHYL-1,3-BENZOXAZOLE has potential applications in materials science, where its properties can be harnessed to develop new materials with specific characteristics for various applications.
Used in Organic Synthesis:
As an organic synthesis compound, 2-(CHLOROMETHYL)-5-METHYL-1,3-BENZOXAZOLE is employed as a reactant or intermediate in the synthesis of complex organic molecules for research and industrial purposes.

InChI:InChI=1/C9H8ClNO/c1-6-2-3-8-7(4-6)11-9(5-10)12-8/h2-4H,5H2,1H3

Upstream product

• 79-04-9 chloroacetyl chloride 
• 95-84-1 3-amino-4-hydroxytoluene 
• 36743-66-5 ethyl chloroacetimidate hydrochloride 
• 74974-54-2 2-chloro-1,1,1-trimethoxyethane 

Downstream Products

• 143708-02-5 5-Ethyl-6-methyl-3-[(5-methyl-benzooxazol-2-ylmethyl)-amino]-1H-pyridin-2-one 
• 1201041-78-2 (R)-1-(5-methyl-benzooxazol-2-ylmethyl)-3-((S)-2-phenyl-2-piperidin-1-yl-propionyloxy)-1-azonia-bicydo[2.2.2]octane chloride 
• 1393643-85-0 C₂₀H₂₁N₅OS 

Relevant academic research and scientific papers

COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF

The present invention provides a compound having a specific chemical structure and having PDE9A inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention provides a composition containing the compound or a pharmaceutically acceptable salt thereof. The present invention provides a pharmaceutical use, for treating or preventing PDE9A-related diseases, of the compound according to the present invention, a salt thereof, and a composition containing the compound or salt. The present invention also provides a method for treating or preventing PDE9A-related diseases, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition containing the compound or salt to a subject in need of treatment.

Anti-oligomerization sheet molecules: Design, synthesis and evaluation of inhibitory activities against α-synuclein aggregation

Aggregation of α-synuclein (α-Syn) play a key role in the development of Parkinson Disease (PD). One of the effective approaches is to stabilize the native, monomeric protein with suitable molecule ligands. We have designed and synthesized a series of sheet-like conjugated compounds which possess different skeletons and various heteroatoms in the two blocks located at both ends of linker, which have good π-electron delocalization and high ability of hydrogen-bond formation. They have shown anti-aggregation activities in vitro towards α-Syn with IC50 down to 1.09 μM. The molecule is found binding in parallel to the NACore within NAC domain of α-Syn, interfering aggregation of NAC region within different α-Syn monomer, and further inhibiting or slowing down the formation of α-Syn oligomer nuclei at lag phase. The potential inhibitor obtained by our strategy is considered to be highly efficient to inhibit α-Syn aggregation.

1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS

The invention provides named compounds of formula (I), pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions and their use in therapy.